Anacor Pharmaceuticals Announces First Quarter 2014 Financial Results Conference Call and Webcast

PALO ALTO, Calif.--(BUSINESS WIRE)--

Anacor Pharmaceuticals, Inc. ANAC will release its financial results for the first quarter ended March 31, 2014, on Wednesday, May 7, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 4:30 p.m. ET / 1:30 p.m. PT during which management will discuss the company's financial results and recent developments. The call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and may be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com where it will be available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — Kerydin, an antifungal for the treatment of mild-to-moderate onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis and psoriasis. In addition to its two lead product candidates, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to Kerydin and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. Anacor has also discovered three other compounds that have been out-licensed for further development — one is licensed to Eli Lilly and Company for the treatment of an animal health indication, the second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline, LLC for tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in earlier stages of research and pre-clinical development. For more information, visit http://www.anacor.com.